证券代码：002390 证券简称：信邦制药 公告编号：2024-037 贵州信邦制药股份有限公司 2023年度股东大会决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示 1、本次股东大会无增加、否决或修改提案的情况。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开情况 1、会议通知情况 贵州信邦制药股份有限公司（以下简称"公司"）于 2024 年 4 月 16 日 在 《 中 国 证 券 报 》 、 《 证 券 时 报 》 和 巨 潮 资 讯 网 （http://www.cninfo.com.cn）刊登了《关于召开 2023 年度股东大 会的公告》（公告编号：2024-030）。 2、会议召集人：公司第九届董事会 3、会议主持人：董事长安吉女士 4、会议时间：2024 年 5 月 8 日 下午 14：00 5、会议地点：贵州省贵阳市乌当区新添大道北段 83 号科开 1 号苑 15 楼会议室 6、股权登记日：2024 年 4 月 29 日 7、召开方式：现场书面投票与网络投票相结合的方式 8、本次股东大会的召集、召开符合《公 ...

证券代码：002390 证券简称：信邦制药 公告编号：2024-036 贵州信邦制药股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 贵州信邦制药股份有限公司（以下简称"公司"）于 2023 年 6 月 27 日召开的第八届董事会第十七次会议、第八届监事会第十二次会 议及 2023 年 7 月 13 日召开的 2023 年第一次临时股东大会审议通过 了《关于回购公司股份方案的议案》，并于 2023 年 7 月 14 日披露了 《回购股份报告书》，具体内容可参见公司刊登于中国证券报、证券 时报及巨潮资讯网（http://www.cninfo.com.cn）的相关公告。 一、回购股份的进展情况 根据《上市公司股份回购规则》、《深圳证券交易所上市公司自律 监管指引第 9 号—回购股份》等相关规定，上市公司在回购期间应当 在每个月的前三个交易日内披露截至上月末的回购进展情况。现将公 司回购股份的进展情况公告如下： 截至 2024 年 4 月 30 日，公司累计回购股份数量为 37,232,540 股，占公司总股本的 1.92%， ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 贵州信邦制药股份有限公司（以下简称"公司"）于近日收到 公司控股股东贵州金域实业投资合伙企业（有限合伙）（以下简称 "金域实业"）的通知，获悉其将所持有的公司部分股份办理了质 押业务，具体情况如下： 本次质押事项已在中国证券登记结算有限责任公司深圳分公司 办理完成质押登记手续，本次质押的股份不涉及负担重大资产重组等 业绩补偿义务。 二、股东股份累计质押情况 截至2024年4月29日，金域实业及其一致行动人安怀略先生、安 吉女士所持质押股份情况如下： 证券代码：002390 证券简称：信邦制药 公告编号：2024-035 贵州信邦制药股份有限公司 关于控股股东部分股份质押的公告 贵州信邦制药股份有限公司 董 事 会 二〇二四年五月六日 股东 名称 是否为控 股股东或 第一大股 东及其一 致行动人 本次质押 股份数量 （股） 占其所 持股份 比例 （%） 占公司 总股本 比例 （%） 是否为 限售股 是否为 补充质 押 质押 起始日 质押 到期日 质权人 质押用途 金域 实业 是 64,000,000 17.78 3 ...

证券代码：002390 证券简称：信邦制药 公告编号：2024-034 贵州信邦制药股份有限公司 关于诉讼事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示 1、案件所处的诉讼阶段：一审判决。 2、上市公司所处的当事人地位：被告。 3、涉案的金额：不涉及。 4、对公司本期利润或期后利润的可能影响：不会对公司本期利 润或期后利润造成直接影响。 贵州信邦制药股份有限公司（以下简称"公司"）于近日收到 贵州省罗甸县人民法院送达的《民事判决书》（（2024）黔 2728 民 初 542 号），现就本次涉及诉讼事项的进展情况公告如下： 三、是否有其他尚未披露的诉讼仲裁事项 除本次披露的诉讼，截至本公告披露日，公司及控股子公司不 存在应披露而未披露的其他重大诉讼、仲裁事项；小额诉讼、仲裁 事项，已在相关年度报告、半年度报告中进行披露。 四、本次公告的诉讼、仲裁对公司本期利润或期后利润的可能 影响 本次判决为一审判决，是否为终审判决存在不确定性。本案涉及 决议撤销纠纷，不涉及金额，不会对公司本期利润或期后利润造成直 接影响。 一、本次诉讼的基本情况 2 ...

Financial Performance - Revenue for Q1 2024 was CNY 1,582,449,461.55, a decrease of 1.41% compared to CNY 1,605,127,137.43 in the same period last year[2] - Net profit attributable to shareholders increased by 11.11% to CNY 58,824,843.56 from CNY 52,944,770.89 year-on-year[2] - Total operating revenue for Q1 2024 was CNY 1,582,449,461.55, a decrease of 1.5% compared to CNY 1,605,127,137.43 in Q1 2023[14] - Net profit for Q1 2024 increased by 14.5% to CNY 71,693,790.38, compared to CNY 62,648,520.70 in Q1 2023[16] - The company achieved a net profit margin of 20% in the latest quarter, reflecting strong operational efficiency[21] Cash Flow and Assets - Net cash flow from operating activities rose by 16.92% to CNY 2,547,325.59 compared to CNY 2,178,740.78 in the previous year[2] - As of March 31, 2024, the company's cash and cash equivalents decreased to RMB 613,968,235.38 from RMB 805,982,979.14 at the beginning of the period, representing a decline of approximately 23.8%[10] - Cash and cash equivalents at the end of Q1 2024 were CNY 543,901,118.54, down from CNY 811,830,576.17 at the end of Q1 2023[19] - Total assets at the end of Q1 2024 were CNY 9,130,430,923.02, down 1.24% from CNY 9,244,971,150.19 at the end of the previous year[2] - Total assets as of March 31, 2024, amounted to RMB 9,130,430,923.02, down from RMB 9,244,971,150.19 at the beginning of the period, a decrease of about 1.2%[12] Liabilities and Equity - Total liabilities decreased to RMB 1,954,725,806.53 from RMB 2,102,884,529.82, a reduction of approximately 7.0%[13] - The weighted average return on equity increased by 0.09 percentage points to 0.86% from 0.77% year-on-year[2] - The company's retained earnings increased to RMB 591,139,993.39 from RMB 532,315,149.83, reflecting an increase of about 11.0%[13] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 73,112[6] - The top two shareholders held a combined 36.98% of the shares, with Guizhou Jinyu Industrial Investment Partnership holding 18.52% and Harbin Yuxi Venture Capital holding 18.46%[6] - The total number of shares repurchased by Guizhou Xibang Pharmaceutical Co., Ltd. is 37,232,540, accounting for 1.92% of the total share capital[8] - The total amount spent on share repurchase is RMB 164,864,261, with a maximum transaction price of RMB 4.87 per share and a minimum of RMB 3.31 per share[8] Operating Expenses - Total operating costs decreased by 2.3% to CNY 1,499,475,395.38 from CNY 1,535,323,707.21 in the previous year[14] - Financial expenses decreased by 56.33% to CNY 4,882,360.02 compared to CNY 11,180,591.06 in the same period last year due to reduced bank borrowings[4] - The company experienced a 758.24% increase in other operating expenses, totaling CNY 1,287,768.48, attributed to donations and other expenditures[4] Research and Development - Research and development expenses increased to CNY 865,885.03 from CNY 691,393.55, reflecting a focus on innovation[14] - R&D investment increased by 30% year-over-year, focusing on innovative drug development[21] Future Plans and Market Strategy - The company plans to use its own funds to repurchase shares for employee stock ownership plans, with a total repurchase amount between RMB 100 million and RMB 200 million[8] - The company plans to launch three new products in the next quarter, targeting a market expansion of 10%[21] - Guizhou Xibang aims for a revenue guidance of 1.2 billion yuan for the next fiscal year, representing a 12% growth target[21] - The company is exploring potential acquisitions to enhance its market presence and product portfolio[21] - Market expansion efforts are expected to contribute an additional 5% to overall revenue in the upcoming year[21] - Strategic partnerships are being formed to enhance distribution channels and improve market reach[21] Customer and Production Metrics - User data showed a growth of 25% in active customers compared to the previous quarter[21] - The company reported a 40% increase in production capacity due to recent technological upgrades[21] Audit and Compliance - The company has not undergone an audit for the Q1 2024 report[20]

证券代码：002390 证券简称：信邦制药 公告编号：2024-033 贵州信邦制药股份有限公司 关于参加投资者集体接待日活动暨2023年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 贵州信邦制药股份有限公司（以下简称“公司”）已于 2024 年 4 月 16 日在巨潮资讯网（www.cninfo.com.cn）披露了《2023 年年 度报告》，为加强公司与投资者的交流互动，便于投资者进一步了 解公司 2023 年度经营情况及其他关切问题，公司将参加在贵州证监 局指导下，贵州证券业协会联合深圳市全景网络有限公司举办的 2024 年贵州辖区上市公司投资者集体接待日（2023 年度业绩说明 会）活动，具体安排如下： 一、业绩说明会的安排 召开时间：2024 年 5 月 9 日 15:40-17:30。 召开方式：网络远程方式。 ...

买入（维持） 报告原因：业绩点评 公 司 研 究 医 药 生 物 2024年04月19日 杜永宏 S0630522040001 dyh@longone.com.cn 证券分析师 伍可心 S0630522120001 wkx@longone.com.cn 信邦制药（002390）：整体经营稳健，中 药饮片快速放量 ——公司简评报告 投资要点 利润端快速增长，现金流持续改善。2023年公司实现营收64.61亿元，同比增长1.75%； 归母净利润2.87亿元，同比增长28.02%；扣非后归母净利润2.68亿元，同比增长19.43%； 主要受去年同期存在股份支付事项的影响等。经营活动产生的现金流量净额7.91亿元，同 比增长33.82%，主要为销售回款总体较好且预付款采购减少。2023年Q4单季实现营收 16.38亿元，同比下降1.57%；归母净利润0.41亿元，同比增长344.08%；扣非后归母净利 润0.21亿元，同比增长0.89%。公司业绩稳健，利润端快速增长。 投资建议：我们预计公司2024-2026年营收分别74.65/81.61/88.52亿元，归母净利润分别 为3.79/4.43/5.05亿元，对应EP ...

Financial Performance - The company's operating revenue for 2023 was ¥6,460,841,315, representing a 1.75% increase compared to ¥6,350,025,827 in 2022[24]. - The net profit attributable to shareholders for 2023 was ¥287,232,798.94, a 28.02% increase from ¥224,479,086.87 in 2022[24]. - The net cash flow from operating activities increased by 33.82% to ¥790,618,030.35 in 2023, up from ¥590,796,585.74 in 2022[24]. - Basic earnings per share rose to ¥0.15 in 2023, a 25.00% increase from ¥0.12 in 2022[25]. - The total assets at the end of 2023 were ¥9,244,971,150, a decrease of 5.60% from ¥9,793,091,573 at the end of 2022[25]. - The net assets attributable to shareholders increased by 0.65% to ¥6,852,401,324 at the end of 2023, compared to ¥6,808,451,646 at the end of 2022[25]. - The company reported a quarterly revenue of ¥1,637,633,668.59 in Q4 2023, with a net profit of ¥40,657,799.79 attributable to shareholders[30]. - The company recognized government subsidies amounting to ¥5,220,236.61 in 2023, down from ¥6,534,540.95 in 2022[31]. - The company achieved operating revenue of 646,084.13 million yuan in 2023, a year-on-year increase of 1.75%[80]. - Net profit attributable to shareholders reached 28,723.28 million yuan, reflecting a year-on-year growth of 28.02%[80]. - The company’s basic earnings per share increased by 25.00% to 0.15 yuan per share[80]. Dividend Distribution - The company reported a total share capital of 1,943,851,868 shares, with a profit distribution plan proposing a cash dividend of 0.60 RMB per 10 shares[4]. - The company plans to distribute dividends based on a total share capital of 1,906,619,328 shares after accounting for repurchased shares[4]. - The profit distribution plan for 2022 included a cash dividend of CNY 0.60 per 10 shares, totaling CNY 116,631,112.08, based on a total share capital of 1,943,851,868 shares[182]. - The company plans to distribute a cash dividend of 0.60 CNY per 10 shares, totaling 114,397,159.68 CNY, with a cash dividend payout ratio of 100% of the distributable profit[184]. - The total cash dividend, including other methods, amounts to 279,261,420.68 CNY, based on a total share capital of 1,943,851,868 shares, excluding 37,232,540 shares repurchased[184]. Risk Management - The company emphasizes that forward-looking statements regarding future plans and strategies do not constitute a commitment to investors, highlighting potential risks[4]. - The company has a comprehensive risk disclosure in the section discussing future development outlooks[4]. - The company faces risks including industry policy changes, market competition, rising costs, and human resource challenges[130][131]. - The company anticipates increased pressure on profit margins due to declining drug prices and intensified regulatory scrutiny[130]. - The company is committed to addressing potential risks proactively to ensure sustainable high-quality development[133]. Market Position and Strategy - The company operates multiple subsidiaries, including Guizhou Keke Pharmaceutical Co., Ltd. and Guizhou Tongde Pharmaceutical Co., Ltd., enhancing its market presence[16]. - The company is positioned to benefit from the ongoing healthcare reforms and the increasing demand for personalized and high-end medical services[42]. - The healthcare market is expected to grow due to rising disposable income and changing consumer expectations for healthcare services[42]. - The company is focused on high-quality development in the pharmaceutical industry, responding to both challenges and opportunities presented by recent policy changes[40]. - The overall healthcare market in China is projected to expand as the government continues to enhance the medical security system and promote healthcare accessibility[40]. - The company aims to enhance its medical service quality through centralized management and strategic cooperation with Jiangsu Provincial Hospital of Traditional Chinese Medicine[65]. - The company plans to expand its market share in the pharmaceutical distribution sector by enhancing supply chain construction and providing diversified services[66]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach, with a budget of 300 million yuan set aside for this purpose[136]. Research and Development - The company is investing heavily in R&D, with an allocation of 200 million yuan, which is 16.7% of total revenue, aimed at developing innovative pharmaceutical products[136]. - Research and development (R&D) investment amounted to ¥4,672,953.58, representing a significant increase of 287.11% year-on-year[106]. - The number of R&D personnel increased to 19, a rise of 72.73% from 11 in the previous year[106]. - The company is focusing on the development of high-end products from traditional Chinese medicine, aiming to enhance market competitiveness[103]. - The company has published over 40 academic papers in reputable journals, reflecting its commitment to research and development in the pharmaceutical field[158]. Corporate Governance - The company has outlined its governance structure and social responsibility initiatives in the annual report, reflecting its commitment to ethical practices[6]. - The company has established a complete independent financial accounting department and maintains an independent accounting system[143]. - The company has a fully independent employee management system, ensuring that all senior management personnel are dedicated to the company[143]. - The board of directors has set up four specialized committees to provide professional opinions and references for decision-making[140]. - The company emphasizes investor relations management, utilizing various methods to enhance communication with investors[142]. - The company adheres to strict information disclosure obligations, ensuring timely and accurate reporting[141]. Environmental Compliance - Guizhou Xibang Pharmaceutical Co., Ltd. strictly adheres to the "Water Pollutants Discharge Standard for Traditional Chinese Medicine Pharmaceutical Industry" (GB21906-2008) for liquid pollutants discharge[194]. - The company has a wastewater discharge agreement with the local sewage treatment plant, ensuring compliance with environmental standards[194]. - The solid waste management follows the "National Hazardous Waste List" and "Medical Waste Management Regulations" for hospitals[194]. - The wastewater discharge permit for Guizhou Xibang Pharmaceutical was issued on August 18, 2023, valid until August 17, 2028[194]. - The total CODcr discharge for Guizhou Xibang Pharmaceutical was 7.271 tons, with an average concentration of 169.92 mg/L, which is within the standard limits[196]. - The hospital's medical waste management reported 194.03 tons of infectious medical waste and 16.59 tons of pathological medical waste, all managed according to regulations[198]. - The company has received multiple environmental impact assessments for its production lines, ensuring compliance with environmental regulations[194]. Employee Development - The total number of employees at the end of the reporting period was 5,149, with 4,862 from major subsidiaries[175]. - The company conducted 920 training sessions in 2023, training a total of 19,145 participants, with an expenditure of CNY 1.1296 million[178]. - The company has established a comprehensive training system to enhance employee skills and support sustainable development[180]. - The company emphasizes a salary policy that reflects market conditions and employee contributions, aiming for a fair and motivating compensation structure[177]. - The company has 3,000 technical personnel, representing approximately 58.2% of the total workforce[175].

2023年度对会计师事务所履职情况评估报告 贵州信邦制药股份有限公司董事会审计委员会 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上 市公司治理准则》、《国有企业、上市公司选聘会计师事务所管理办法》、 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司 规范运作（2023 年修订）》和贵州信邦制药股份有限公司（以下简称 "公司"）的《公司章程》、《董事会审计委员会工作细则》等规定和 要求，董事会审计委员会本着勤勉尽责的原则，恪尽职守，认真履职。 董事会审计委员会对大华会计师事务所（特殊普通合伙）（以下简称 "大华"）2023 年度履职评估及履行监督职责的情况报告如下： 计师 1,471 人，其中签署过证券服务业务审计报告的注册会计师 1,141 人。 大华 2022 年经审计的业务收入总额人民币 332,731.85 万元，其 中审计业务收入人民币 307,355.10 万元（其中证券业务收入人民币 138,862.04 万元）。 大华 2022 年上市公司年报审计客户家数为 488 家，上市公司财 务报表审计收费总额人民币 61,034.29 万元。这些上市公司主要行业 涉及制造业 ...

本人已对报告期内本人任职期间（以下简称"任职期间"）的独 立性情况进行了自查，并将独立性自查情况提交董事会。经自查，本 人任职符合《上市公司独立董事管理办法》等法律、法规、规范性文 件及《公司章程》、《独立董事工作制度》规定的关于独立董事独立 1 性的要求，不存在影响独立性的情况。 贵州信邦制药股份有限公司 2023年度独立董事述职报告 作为贵州信邦制药股份有限公司（以下简称"公司"）的独立董 事，本人严格按照《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公 司治理准则》、《上市公司独立董事管理办法》等有关法律、法规、 规范性文件及《公司章程》、《独立董事工作制度》的有关规定，尽 职尽责，忠实、勤勉地履行独立董事义务，积极出席相关会议，认真 审议董事会各项议案，充分发挥了独立董事的独立作用，切实维护了 公司及全体投资者，尤其是中小投资者的合法权益。现就报告期内本 人任职期间履行独立董事职责情况述职如下： 一、基本情况 本人周俊，中国籍，1968 年出生，无境外永久居留权，华东理 工大学制药专业学士，格勒诺布尔大学 EMBA，曾任成都倍特药业股 ...